ELV
Income statement / Annual
Last year (2023), Elevance Health Inc.'s total revenue was $171.34 B,
an increase of 9.42% from the previous year.
In 2023, Elevance Health Inc.'s net income was $5.99 B.
See Elevance Health Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$171.34 B
|
$156.60 B
|
$138.64 B
|
$121.87 B
|
$104.21 B
|
$92.11 B
|
$90.04 B
|
$84.86 B
|
$79.16 B
|
$73.87 B
|
Cost of Revenue |
$17.29 B |
$13.04 B |
$10.90 B |
$8.95 B |
$1.99 B |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit |
$154.05 B |
$143.56 B |
$127.74 B |
$112.91 B |
$102.22 B |
$92.11 B |
$90.04 B |
$84.86 B |
$79.16 B |
$73.87 B |
Gross Profit Ratio |
0.9 |
0.92 |
0.92 |
0.93 |
0.98 |
1 |
1 |
1 |
1 |
1 |
Research and Development
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$11.25 B
|
$11.17 B
|
$11.09 B
|
$10.26 B
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.40 B
|
$1.39 B
|
$1.44 B
|
$1.49 B
|
Selling, General &
Administrative Expenses |
$36.45 B
|
$17.69 B
|
$15.91 B
|
$17.45 B
|
$13.36 B
|
$14.02 B
|
$12.65 B
|
$12.56 B
|
$12.53 B
|
$11.75 B
|
Other Expenses |
$38.27 B |
-$31.45 B |
-$27.05 B |
-$26.11 B |
-$15.69 B |
-$14.37 B |
-$12.82 B |
-$12.72 B |
$0.00 |
$0.00 |
Operating Expenses |
$38.27 B |
$17.69 B |
$15.91 B |
-$126.01 B |
-$98.23 B |
-$86.28 B |
$12.65 B |
$12.56 B |
$12.53 B |
$11.75 B |
Cost And Expenses |
$163.63 B |
$148.83 B |
$130.71 B |
$115.63 B |
$98.23 B |
$87.04 B |
$86.08 B |
$80.31 B |
$74.53 B |
$69.51 B |
Interest Income |
$1.03 B |
$855.00 M |
$802.00 M |
$785.00 M |
$745.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Interest Expense |
$1.03 B |
$851.00 M |
$798.00 M |
$784.00 M |
$746.00 M |
$753.00 M |
$739.00 M |
$723.00 M |
$653.00 M |
$600.70 M |
Depreciation &
Amortization |
$1.75 B
|
$1.68 B
|
$1.30 B
|
$1.15 B
|
$485.00 M
|
$482.00 M
|
$279.10 M
|
$296.30 M
|
$907.90 M
|
$851.00 M
|
EBITDA |
$1.74 B
|
$9.44 B
|
$9.23 B
|
$7.39 B
|
$7.12 B
|
$6.20 B
|
$4.85 B
|
$5.47 B
|
$5.54 B
|
$5.22 B
|
EBITDA Ratio |
0.01 |
0.06 |
0.07 |
0.06 |
0.07 |
0.07 |
0.05 |
0.06 |
0.07 |
0.07 |
Operating Income Ratio
|
-0
|
0.05
|
0.06
|
0.05
|
0.06
|
0.06
|
0.04
|
0.05
|
0.06
|
0.06
|
Total Other
Income/Expenses Net |
$7.72 B
|
-$851.00 M
|
$12.65 B
|
$10.38 B
|
-$82.87 B
|
-$753.00 M
|
$33.10 M
|
$35.10 M
|
$43.10 M
|
$41.30 M
|
Income Before Tax |
$7.72 B |
$7.77 B |
$7.93 B |
$6.24 B |
$5.99 B |
$5.07 B |
$3.96 B |
$4.56 B |
$4.63 B |
$4.37 B |
Income Before Tax Ratio
|
0.05
|
0.05
|
0.06
|
0.05
|
0.06
|
0.06
|
0.04
|
0.05
|
0.06
|
0.06
|
Income Tax Expense |
$1.72 B |
$1.75 B |
$1.83 B |
$1.67 B |
$1.18 B |
$1.32 B |
$121.00 M |
$2.09 B |
$2.07 B |
$1.81 B |
Net Income |
$5.99 B |
$5.89 B |
$6.16 B |
$4.57 B |
$4.81 B |
$3.75 B |
$3.84 B |
$2.47 B |
$2.56 B |
$2.57 B |
Net Income Ratio |
0.03 |
0.04 |
0.04 |
0.04 |
0.05 |
0.04 |
0.04 |
0.03 |
0.03 |
0.03 |
EPS |
25.38 |
24.56 |
25.04 |
18.23 |
18.81 |
14.75 |
15.01 |
9.36 |
9.8 |
9.58 |
EPS Diluted |
25.22 |
24.28 |
24.73 |
17.98 |
18.47 |
14.75 |
14.35 |
9.21 |
9.38 |
8.99 |
Weighted Average Shares
Out |
$235.90 M
|
$240.00 M
|
$243.80 M
|
$250.80 M
|
$255.50 M
|
$254.30 M
|
$256.08 M
|
$263.75 M
|
$261.24 M
|
$268.11 M
|
Weighted Average Shares
Out Diluted |
$237.40 M
|
$242.80 M
|
$246.80 M
|
$254.30 M
|
$260.30 M
|
$254.30 M
|
$267.80 M
|
$268.10 M
|
$272.90 M
|
$285.90 M
|
Link |
|
|
|
|
|
|
|
|
|
|